LZQ Cream contains Luliconazole 1% w/w, an imidazole antifungal agent indicated for the topical treatment of superficial fungal infections of the skin, including dermatophytosis, candidiasis, and pityriasis versicolor. Luliconazole exhibits broad-spectrum antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. The cream formulation allows for effective penetration into the stratum corneum, ensuring targeted delivery to the site of infection. LZQ Cream is typically applied once daily to the affected area and surrounding skin after cleansing and drying, with treatment duration varying according to the specific infection and clinical response, generally ranging from one to two weeks. It is well tolerated, with adverse effects limited primarily to mild local reactions such as burning, itching, or erythema at the application site. LZQ Cream is contraindicated in patients with known hypersensitivity to luliconazole or any excipients in the formulation. Caution is advised when applying near mucous membranes or broken skin. LZQ Cream offers a convenient and effective topical option for managing common superficial fungal infections, promoting rapid symptom resolution and reducing the risk of recurrence when used as directed.